Comparison of short ‐term outcomes following minimally invasive versus open Sweet esophagectomy for Siewert type II adenocarcinoma of the esophagogastric junction

BackgroundSurgical resection is still the main treatment option for patients with resectable Siewert type II adenocarcinoma of the esophagogastric junction (AEG). This retrospective study evaluated the significance of minimally invasive Sweet esophagectomy (MISE) for the treatment of Siewert type II AEG.MethodsWe retrospectively evaluated 174 patients with Siewert type II AEG who received a Sweet esophagectomy in our center between October 2013 and September 2017. Of these patients, 73 underwent MISE and 101 underwent open Sweet esophagectomy (OSE). The clinicopathologic factors, operational factors and postoperative complications were compared.ResultsThe two groups were similar in terms of age, sex, American Society of Anesthesiologists grade, preoperative staging and incidence of comorbidities (P >  0.05). Relative to the OSE approach, the MISE approach was associated with a significant decrease in surgical blood loss (P 
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Neuroendocrine Tumor;   Anaplastic Thyroid Cancer;   Adenocarcinoma;   Pheochromocytoma;   Paraganglioma Intervention:   Drug: Cabozantinib 40 mg Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   Ipsen;   Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Solid Tumor;   Gastric Cancer;   Pancreatic Adenocarcinoma Intervention:   Drug: AB011 Injection Sponsors:   Carsgen Therapeutics, Ltd.;   Shanghai East Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Cancer;   Non-metastatic Prostate Cancer;   Metastatic Prostate Cancer;   Prostate Adenocarcinoma;   Metastatic Prostate Carcinoma in the Soft Tissue;   Prostate Cancer Metastatic Intervention:   Sponsors:   Imperial College London;   Imperial Clinical Trials Unit (ICTU);   Wellcome Trust Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Solid Tumor;   Gastric Cancer;   Pancreatic Adenocarcinoma Intervention:   Drug: AB011 Injection Sponsors:   Carsgen Therapeutics, Ltd.;   Shanghai East Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Cancer;   Non-metastatic Prostate Cancer;   Metastatic Prostate Cancer;   Prostate Adenocarcinoma;   Metastatic Prostate Carcinoma in the Soft Tissue;   Prostate Cancer Metastatic Intervention:   Sponsors:   Imperial College London;   Imperial Clinical Trials Unit (ICTU);   Wellcome Trust Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Neuroendocrine Tumor;   Anaplastic Thyroid Cancer;   Adenocarcinoma;   Pheochromocytoma;   Paraganglioma Intervention:   Drug: Cabozantinib 40 mg Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   Ipsen;   Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS miR-4448 can inhibit A549 cell proliferation and metastasis. miR-4448 in exosomes has the potential to serve as a diagnostic marker of patients with adenocarcinoma metastasis. PMID: 32444593 [PubMed - as supplied by publisher]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Publication date: Available online 23 May 2020Source: Annals of Medicine and SurgeryAuthor(s): Shun Iwai, Aika Funasaki, Atsushi Sekimura, Nozomu Motono, Katsuo Usuda, Sohsuke Yamada, Yoshimichi Ueda, Kyouta Akasaki, Kouta Tanimura, Kazumasa Kase, Hidetaka Uramoto
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
More News: Adenocarcinoma | Anesthesia | Anesthesiology | Cancer | Cancer & Oncology | Esophagectomy | Respiratory Medicine | Study